2-cyano-N-(4-nitrophenyl)aziridine-1-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-cyano-N-(4-nitrophenyl)aziridine-1-carboxamide
• 化学式: C₁₀H₈N₄O₃
• 分子量: 232.199
• InChiKey: BYLITRSLCIHTGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  异氰酸对硝基苯 、 2-氮丙啶甲腈 以 甲苯 为溶剂， 以89%的产率得到2-cyano-N-(4-nitrophenyl)aziridine-1-carboxamide
  参考文献：
  名称：

  Novel Antitumor 2-Cyanoaziridine-1-carboxamides

  摘要：

  A set of 20 2-cyanoaziridine-1-carboxamides was synthesized from 2-cyanoaziridine and appropriate isocyanates. These compounds were active against a variety of solid and hematological tumor cells in culture, including strains resistant to doxorubicin and mitoxantrone. Their potencies in these assays correlated with the lipophilicity of substituents. The N-phenyl derivative was more potent and equally effective to imexon, a cyclized 2-cyanoaziridine-1-carboxamide of clinical interest, against cloned fresh human tumors.

  DOI：

  10.1021/jm980600x

文献信息

• Liposomal imexon
  申请人：——

  公开号：US20030129222A1

  公开（公告）日：2003-07-10

  Disclosed are novel compositions comprising a lipid and imexon or a derivative thereof. Also disclosed are liposomal compositions comprising imexon or a derivative thereof. Methods for administrating pharmaceutically acceptable compositions comprising a lipid and imexon or a derivative thereof for the treatment of diseases, such as cancer, are also disclosed herein.

  披露了包含脂质和伊美酮或其衍生物的新型组合物。还披露了包含伊美酮或其衍生物的脂质体组合物。本文还披露了用于治疗疾病（如癌症）的含有脂质和伊美酮或其衍生物的药用合成物的管理方法。
• NOVEL CYANOAZIRIDINES FOR TREATING CANCER
  申请人：Amplimed, Inc.

  公开号：EP1027041B1

  公开（公告）日：2003-10-22
• US6297230B1
  申请人：——

  公开号：US6297230B1

  公开（公告）日：2001-10-02
• Novel Antitumor 2-Cyanoaziridine-1-carboxamides
  作者：Bhashyam S. Iyengar、Robert T. Dorr、David S. Alberts、Evan M. Hersh、Sydney E. Salmon、William A. Remers

  DOI：10.1021/jm980600x

  日期：1999.2.1

  A set of 20 2-cyanoaziridine-1-carboxamides was synthesized from 2-cyanoaziridine and appropriate isocyanates. These compounds were active against a variety of solid and hematological tumor cells in culture, including strains resistant to doxorubicin and mitoxantrone. Their potencies in these assays correlated with the lipophilicity of substituents. The N-phenyl derivative was more potent and equally effective to imexon, a cyclized 2-cyanoaziridine-1-carboxamide of clinical interest, against cloned fresh human tumors.